A practical reference on deamidation: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-28. Anything still debated is marked as such rather than presented as settled.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
Verification of research-grade material involves checking purity, sequence and counter-ion content against a certificate of analysis. Reported purity figures usually reflect chromatographic area percentage and do not by themselves establish biological activity. Independent laboratories may repeat mass confirmation and peptide mapping to detect substitutions or truncations. Open questions concern how residual solvents, trace metals and subtle conformational variants affect measured behavior, and how consistently different suppliers define their specifications. Documentation of analytical methods matters as much as the headline purity number when results are compared across studies.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual inspection serves only as a preliminary check |
| Solubility | Freely soluble in water and aqueous buffers | Gentle mixing may be needed to reach full dissolution |
| Typical storage | Minus 20 degrees Celsius or colder, desiccated, protected from light | Avoid repeated freeze-thaw cycles |
| Primary analytical method | Reversed-phase HPLC with mass detection | Purity reported as chromatographic area percent |
| Common synonyms | GIP/GLP-1 dual agonist; LY3298176 | Development codes are distinct from approved product names |
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Characterization of the peptide relies on reversed-phase high-performance liquid chromatography for purity and related-substance profiling, with ultraviolet detection near 214 nanometers. Mass spectrometry confirms molecular mass and reveals modifications such as oxidation or deamidation. Peptide mapping after enzymatic digestion verifies the amino acid sequence, while amino acid analysis supplies compositional data. Circular dichroism and infrared spectroscopy are used to assess secondary structure, particularly the alpha-helical content that influences aggregation behavior in solution.
Common degradation routes include hydrolysis of labile amide bonds, deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation. Aggregates can form during freeze-thaw cycling, at elevated pH, or when peptide concentration is high. Each route produces characteristic chromatographic or mass shifts that are tracked during stability studies. Whether a given minor impurity alters biological activity is often an open question, and specification limits are typically set on identity and purity rather than on functional data for trace species.
Lyophilized material is generally held at -20 degrees Celsius or lower, desiccated and protected from light, where it remains stable for extended periods. Reconstituted or ready-to-use solution is usually kept at 2 to 8 degrees Celsius with minimal agitation. Repeated freeze-thaw cycles should be avoided because they promote aggregation and reduce the soluble monomer fraction. Shipment of frozen solid commonly uses dry ice, while refrigerated liquid moves with validated cold packs. Stability beyond documented periods is not established.
Type V – Having the same clinical features as type IV, it can be clinically distinguished by observing a "mesh-like" appearance to a bone biopsy under a microscope. Type V can be further distinguished from other types of OI by the "V triad": an opaque band (visible on X-ray) adjacent to the growth plates; hypertrophic calluses (abnormally large masses of bony repair tissue) which form at fracture sites during the healing process; and calcification of the interosseous membrane of the forearm, which may make it difficult to turn the wrist. Other features of this condition may include pulled elbow, and, as in other types of OI, long bone bowing and hearing loss. Cases of this type are caused by mutations in the IFITM5 gene on chromosome 11p15.5. The separation of type V from type IV OI, its clinical type, was initially suggested even before its genetic cause was known, by Glorieux et al. in 2000. Type V is relatively common compared to other genetically defined types of OI—4% of OI patients at the genetics department of the Brazilian Hospital de Clínicas de Porto Alegre were found to have it. Type VI – With the same clinical features as type III, it is distinguished by bones which have an appearance similar to that seen in osteomalacia. Type VI is caused by a loss-of-function mutation in the SERPINF1 gene on chromosome 17p13.3. Type VII – OI caused by a mutation in the gene CRTAP on chromosome 3p22.3; clinically similar to OI types II and III, depending on affected individual.
Although the term was coined in the late 1980s one of the first retroactively recognized examples of a killer application is the VisiCalc spreadsheet, released in 1979 for the Apple II. Because it was not released for other computers for 12 months, people spent US$100 (equivalent to $400 in 2025) for the software first, then $2,000 to $10,000 (equivalent to $9,000 to $44,000) on the requisite Apple II. Byte wrote in 1980, "VisiCalc is the first program available on a microcomputer that has been responsible for sales of entire systems", and Creative Computing's VisiCalc review is subtitled "reason enough for owning a computer". Others also chose to develop software, such as EasyWriter, for the Apple II first because of its higher sales, helping Apple defeat rivals Commodore International and Tandy Corporation. The co-creator of WordStar, Seymour Rubinstein, argued that the honor of the first killer app should go to that popular word processor, given that it came out a year before VisiCalc and that it gave a reason for people to buy a computer. However, whereas WordStar could be considered an incremental improvement (albeit a large one) over smart typewriters like the IBM Electronic Selectric Composer, VisiCalc, with its ability to instantly recalculate rows and columns, introduced an entirely new paradigm and capability unavailable on larger computers. Lotus 1-2-3 similarly benefited sales of the IBM PC. Noting that computer purchasers did not want PC compatibility as much as compatibility with certain PC software, InfoWorld suggested "let's tell it like it is.
Following a decentralized strategy, Iranian units responded with a series of missile and drone attacks against Israel and US military bases in the Middle East, attacked US allies in the Middle East, as well as blocked the Strait of Hormuz and subsequently claimed sovereignty over it in late March. Following the strikes on their territory, the United Arab Emirates, Saudi Arabia, Kuwait, and Bahrain also attacked Iran and skirmished with its Iraqi non-state allies. Two days after Khamenei's assassination, fighting resumed between Hezbollah and Israel. Israel began occupying southern Lebanon in March. An escalation of the Yemeni civil war by the Iran-backed Houthi forces in September started the Strait of Bab al-Mandab crisis. The war has resulted in thousands of civilian and military casualties. The economic impact of the war included the largest supply disruption of the global oil market, disruptions of the natural gas, fertilizer, aviation, and tourism industries, and volatility in financial markets. As of September 2026, the US Department of Defense estimated that the war had so far cost $43.6 billion. The secretary-general of the United Nations and several countries condemned the US–Israeli strikes, while the United Nations Security Council passed a resolution condemning Iran's retaliatory strikes on Gulf states. A two-week ceasefire beginning on 8 April came under strain after Iran responded to Israeli attacks on Lebanon by resuming its blockade. After the failure of the Islamabad Talks on 12–13 April, the US imposed its own naval blockade.
The government of Santiago Peña began on 15 August 2023 following his election as President of Paraguay. He was sworn in as president at the age of 44, becoming the youngest president of Paraguay since the restoration of democracy in 1989, surpassing Mario Abdo Benítez, who was 46 years old at the time of his inauguration. In the first days of his term, administrative reforms aimed at the reorganization of the executive branch and the centralization of state functions were promoted. One of the main changes was the creation of the Ministry of Economy and Finance, enacted on 23 August 2023. This new ministry absorbed the functions of the defunct Ministry of Finance, the Technical Secretariat for Economic and Social Development Planning (STP), and the Secretariat of the Civil Service (SFP). Carlos Fernández Valdovinos was appointed as the first minister of this institution. Likewise, the National Directorate of Tax Revenue (DNIT) was established through the merger of the Undersecretariat of State for Taxation (SET) and the National Customs Directorate (DNA). As for the binational entities and other key institutions, Justo Zacarías Irún was appointed acting general director of Itaipu Binacional, while Luis Federico Benítez Cuevas assumed office as acting director of the Yacyretá Binational Entity (EBY). At the National Development Bank (BNF), the presidency was assigned to Manuel Ochipinti. For her part, Liliana Alcaraz was appointed minister of the Secretariat for the Prevention of Money or Asset Laundering (Seprelad).
Sources: en.wikipedia.org
is the unit tensor. This equation can be thought of as a generalized form of Newton's law of viscosity. The bulk viscosity (also called volume viscosity) expresses a type of internal friction that resists the shearless compression or expansion of a fluid. Knowledge of
Javits (1952), former ambassador and permanent U.S. representative to the Conference on Disarmament in Geneva 2001–2003; U.S. permanent representative to the Organisation for the Prohibition of Chemical Weapons 2003–2009 James D. Theberge (1952), former U.S. ambassador to Chile and Nicaragua G. Norman Anderson (1954), former U.S. ambassador to Sudan David J. Bardin (1954), deputy administrator of the Federal Energy Administration; commissioner of the New Jersey Department of Environmental Protection William Haddad (1954), political operative, lobbyist, and journalist, Peace Corps founding official, aide to the Kennedy family, and grandson-in-law of Franklin D. Roosevelt Richard E. Benedick (1955), president emeritus of the National Council for Science and the Environment, ambassador, and chief U.S. negotiator to the Montreal Protocol John L. Hirsch (1957), U.S. ambassador to Sierra Leone 1995–1998 Morton Halperin (1958), deputy assistant secretary of defense, director of policy planning for the U.S. State Department, and member of Richard Nixon's Enemies List Shelby Brewer (1959), assistant secretary of energy for nuclear energy 1981–1984 Benjamin Huberman (1959), acting director of the Office of Science and Technology Policy; acting science advisor to the president in 1981 Pat Mullins (1959), chairman of the Republican Party of Virginia Constantine Menges (1960), national security aide to Ronald Reagan James E.
=== Laboratory Network === Gift of Hope Organ and Tissue Donor Network Laboratory (Itasca) HSHS St. Mary's Hospital Decatur, IL Illinois State University Loyola University Medical Center SHIELD Illinois Clinical Diagnostic Laboratory at UIC SHIELD Illinois COVID-19 Testing Lab (Springfield) SHIELD T3 Kentucky SHIELD T3 Madison SHIELD T3 UIC Simple Labs University of Illinois College of Medicine Rockford University of Illinois Urbana-Champaign Annex
Sources: en.wikipedia.org
Liquid chromatography combined with mass spectrometry is the most common approach. Digestion followed by peptide mapping verifies the sequence and modification sites. Results are judged against a reference standard or a theoretically calculated mass.
Lower temperatures slow most degradation routes, and storage at minus twenty degrees Celsius or below is standard for lyophilized material. Repeated warming and cooling imposes stress on the molecule. Dissolved samples deteriorate faster and are usually handled over shorter periods.
It normally reflects the relative chromatographic area of the principal peak. It does not capture every possible impurity or demonstrate biological function. Additional methods are required to describe a sample completely.
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.